51. Drug composition matters: the influence of carrier concentration on the radiochemical purity, hydroxyapatite affinity and in-vivo bone accumulation of the therapeutic radiopharmaceutical (188)Rhenium-HEDP
- Author
-
Rogier Lange, R. ter Heine, Haiko J. Bloemendal, Ruud M. Ramakers, M.M.L. van der Westerlaken, Freek J. Beekman, N. H. Hendrikse, J.M.H. de Klerk, Clinical pharmacology and pharmacy, and CCA - Innovative therapy
- Subjects
Male ,Drug ,Cancer Research ,medicine.medical_treatment ,media_common.quotation_subject ,chemistry.chemical_element ,Hydroxyapatite binding ,Bone affinity ,Bone and Bones ,Hydroxyapatite ,Mice ,chemistry.chemical_compound ,In vivo ,medicine ,Animals ,Tissue Distribution ,Radiology, Nuclear Medicine and imaging ,media_common ,Radioisotopes ,Radiochemistry ,Rhenium-188 ,Etidronic Acid ,Rhenium-188-HEDP ,Rhenium-HEDP ,Ammonium perrhenate ,Bisphosphonate ,Etidronic acid ,Rhenium ,Mice, Inbred C57BL ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,Durapatite ,chemistry ,Radiology Nuclear Medicine and imaging ,Molecular Medicine ,Composition (visual arts) ,Radiopharmaceuticals ,Nuclear chemistry ,medicine.drug - Abstract
Item does not contain fulltext INTRODUCTION: (188)Rhenium-HEDP is an effective bone-targeting therapeutic radiopharmaceutical, for treatment of osteoblastic bone metastases. It is known that the presence of carrier (non-radioactive rhenium as ammonium perrhenate) in the reaction mixture during labeling is a prerequisite for adequate bone affinity, but little is known about the optimal carrier concentration. METHODS: We investigated the influence of carrier concentration in the formulation on the radiochemical purity, in-vitro hydroxyapatite affinity and the in-vivo bone accumulation of (188)Rhenium-HEDP in mice. RESULTS: The carrier concentration influenced hydroxyapatite binding in-vitro as well as bone accumulation in-vivo. Variation in hydroxyapatite binding with various carrier concentrations seemed to be mainly driven by variation in radiochemical purity. The in-vivo bone accumulation appeared to be more complex: satisfactory radiochemical purity and hydroxyapatite affinity did not necessarily predict acceptable bio-distribution of (188)Rhenium-HEDP. CONCLUSIONS: For development of new bisphosphonate-based radiopharmaceuticals for clinical use, human administration should not be performed without previous animal bio-distribution experiments. Furthermore, our clinical formulation of (188)Rhenium-HEDP, containing 10 mumol carrier, showed excellent bone accumulation that was comparable to other bisphosphonate-based radiopharmaceuticals, with no apparent uptake in other organs. ADVANCES IN KNOWLEDGE: Radiochemical purity and in-vitro hydroxyapatite binding are not necessarily predictive of bone accumulation of (188)Rhenium-HEDP in-vivo. IMPLICATIONS FOR PATIENT CARE: The formulation for (188)Rhenium-HEDP as developed by us for clinical use exhibits excellent bone uptake and variation in carrier concentration during preparation of this radiopharmaceutical should be avoided.
- Published
- 2015
- Full Text
- View/download PDF